Pamiparib + Standard Care for Glioblastoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing pamiparib and olaparib combined with radiation therapy in patients with newly diagnosed and recurrent glioblastoma. These drugs help make cancer cells more sensitive to radiation by stopping them from repairing their DNA. The goal is to see if this combination can improve treatment outcomes for this aggressive brain cancer. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumors.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify if you must stop taking your current medications. However, there is a required washout period of at least 21 days after your last chemotherapy dose before starting the trial, provided you did not receive radiotherapy. Additionally, if you are using coumarin-derived anticoagulants, you must discontinue them before surgery. It's best to discuss your specific medications with the trial team.
Will I have to stop taking my current medications?
The trial does not specify if you must stop all current medications, but you cannot use coumarin-derived anticoagulants unless they can be stopped before surgery. If you have been on chemotherapy, a 21-day washout period (time without taking the medication) is required before starting the trial.
What safety data exists for Pamiparib and standard care in glioblastoma treatment?
The research indicates that Pamiparib, a PARP inhibitor, has been evaluated for its safety and efficacy in combination with temozolomide (TMZ) for brain tumors. Pamiparib shows strong anti-tumor synergy with TMZ and improved penetration across the blood-brain barrier. It has been tested in clinical trials, such as NCT03150862, for its potential in treating brain tumors. Additionally, a Phase I trial of Veliparib, another PARP inhibitor, with standard radiation and TMZ in glioblastoma patients was conducted to determine safety and maximum tolerated dose, suggesting a similar approach could be applicable to Pamiparib.12345
Is Pamiparib safe for use in humans?
Is the drug Pamiparib a promising treatment for glioblastoma?
What makes the drug Pamiparib unique for treating glioblastoma?
Pamiparib is unique because it is a potent PARP inhibitor that can cross the blood-brain barrier more effectively than other similar drugs, making it particularly promising for treating brain tumors like glioblastoma. It also shows strong synergy with temozolomide, a standard treatment for brain tumors, potentially overcoming resistance and improving treatment outcomes.24678
What data supports the idea that Pamiparib + Standard Care for Glioblastoma is an effective treatment?
The available research does not provide specific data on the effectiveness of Pamiparib combined with standard care for glioblastoma. Instead, it focuses on other drugs and treatments like buparlisib and iniparib, which are being tested for glioblastoma. There is also a study on Pamiparib's presence in human plasma and brain tumors, but it does not discuss its effectiveness for glioblastoma. Therefore, there is no direct evidence from the provided information to support the effectiveness of Pamiparib + Standard Care for glioblastoma.2691011
What data supports the effectiveness of the drug Pamiparib in treating glioblastoma?
Pamiparib is a drug that can be measured in both blood and brain tumors, which helps researchers understand how it works in the body. While specific effectiveness data for Pamiparib in glioblastoma is not provided, its ability to reach brain tumors is a positive sign for its potential use in treating this condition.2691011
Who Is on the Research Team?
Nader Sanai, MD
Principal Investigator
Director, Ivy Brain Tumor Center
Are You a Good Fit for This Trial?
Adults with new or recurrent glioblastoma who've had surgery and are set for standard treatment, including radiation. They must be able to swallow pills, have good organ function, not be pregnant or breastfeeding, use effective contraception, and not have severe infections or certain chronic diseases. Those with prior PARP inhibitor treatments or allergic reactions to trial drugs cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 0
Participants receive pamiparib or olaparib for 4 days prior to surgical resection
Exploratory Phase 2
Participants receive pamiparib or olaparib in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Olaparib
- Pamiparib
- Radiation therapy
Pamiparib is already approved in China for the following indications:
- Ovarian cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nader Sanai
Lead Sponsor
BeiGene
Industry Sponsor
Ivy Brain Tumor Center
Collaborator
Barrow Neurological Institute
Collaborator